HIV/AIDS relates to a group of conditions caused by the human immunodeficiency virus (HIV). Around thirty five million individuals worldwide area unit infected with the HIV virus, and since the 1980s, AIDS has caused approximately 36 million deaths. Cannabis oil has been shown to be remarkably effective at treating several important symptoms of HIV/AIDS.
A 2005 review conducted on 523 HIV-positive patients found that 143 (27%) of the respondents used cannabis to regulate their symptoms; of these, an overwhelming 97% reported that they experienced changes in appetite.
In 2007, doublecannabis-HIVAppetite stimulant-blind research was conducted into the effects of smoked cannabis and dronabinol (a synthetic form of THC). This comparison found that both cannabis and dronabinol increased caloric intake compared to placebo, in a dose-dependent manner. The result was characterised by raised frequency of ingestion occasions.
Moreover, ingestion occasions equated 404 kcal across the board, but dronabinol and cannabis caused a significant shift in the administration of nutrient intake–when given placebo, patients derived 51% of their nutrients from carbohydrates, 36% from fat, and 13% from protein; when given dronabinol, fat consumption increased to 40% and carbohydrate consumption decreased, and when given cannabis, protein consumption dropped to 11% while fat consumption tended to increase.
When given high doses of cannabis and psychoactive substance, patients experienced significant increases in body weight. Under placebo circumstances, the respondents’ mean weight was seventy seven.5 kg; after four days of cannabis, patients gained 1.1 kg, and after four days of dronabinol, patients gained 1.2 kg.
Nausea is a common sign of HIV infection, and as the disease grows, the causes of nausea can become increasingly complex. Nausea might arise thanks to channel problems, hepatorenal pathology, central nervous system ailments, or as a result of treatments used to treat the disease.
The ability of cannabis-HIV-anti-nauseanoids and sure artificial analogues to counter the manifestations of nausea in HIV/AIDS patients is well-known; actually, the psychoactive drug analogue psychoactive substance is approved by the US Food & Drug Administration for the treatment of nausea and appetency loss related to cancer and HIV. Early analysis into the psychoactive substance as a treatment for AIDS-induced appetency loss was printed in 1995 and located that patients encountered a mean two hundredth improvement in nausea.
The previously-mentioned 2005 patient survey found that 93% of HIV-positive cannabis users proclaimed subjective improvements in nausea after taking Rick Simpsons Oil half rice grain dosage. Another 2005 investigation found that among HIV-positive patients undergoing nausea, those who used cannabis oil were more likely to adhere to their anti-retroviral therapies than non-users. Patients not plagued by nausea failed to expertise vital changes in adherence if they used cannabis, indicating that adherence was increased by improving symptoms of nausea.
Anxiety, depression and mood complications are a common feature of HIV/AIDS and can arise due to a combination of negative physiological, and social pressures. The 2005 patient survey found that ninety three of respondents knowledgeable relief of tension once victimisation cannabis oil, while 86% reported an improvement in depression too.
The preceding 2007 double-blind comparison into cannabis oil and psychoactive substance found that each substances improved respondents’ mood and caused a “good drug effect” that raised feelings of friendliness, stimulation and self-confidence. Interestingly, lower doses of psychoactive drug appeared to provoke higher rates of tension within the subjects than higher doses of psychoactive drug, or psychoactive substance at any dose.
HIV/AIDS will cause severe and debilitative pain that arises from numerous advanced sources, together with joint, nerve, and muscle pain. A 2011 cross-sectional comparison on 296 socioeconomically underprivileged patients found that fifty three.7% had severe pain, 38.1% had moderate pain, and 8.2% had gentle pain; over [*fr1] the themes had a prescript for an opioid analgesic. More severe pain was also found to correlate with the incidence of depression.
The 2005 patient survey found that 94% of respondents experienced relief from muscle pain as a result of using cannabis; 90% also reported a change in neuropathy (nerve pain) and 85% in paresthesia (burning, tingling and prickling sensations). The fact that willnabis can offer vital long-run subjective relief of chronic pain in HIV/AIDS victims is noteworthy; safer and potentially-cheaper prescriptions that might replace the utilization of opioids in disadvantaged groups could have several positive implications, including a decline in opioid-related deaths and increased availability of medicine to those in need.
Reduces peripheral neuropathy
A specific and especially common form of pain associated with HIV/AIDS is peripheral neuropathy, in which one or more nerves of the peripheral nervous system (any part of the nervous system outside the brain and spinal cord) become damaged and lead to pain, twitching, paresthesia, muscle loss and impaired coordination. It has been shown that willnabis can facilitate improve symptoms of peripheral pathology in HIV/AIDS, as well as in other conditions in which it appears, such as diabetes.
Beyond the above-cannabis-HIV-peripheral pathology mentioned subjective reports of diminished nerve pain and symptom, several other considerations have assessed the ability of cannabis to improve peripheral neuropathy in HIV/AIDS patients. In 2007, a patient survey conducted in the U.S., Puerto Rico, Colombia and Taiwan found that 67 of 450 patients with peripheral neuropathy reported the use of cannabis to improve their symptoms.
A randomized placebo-controlled trial also printed in 2007 found that pain was lessened by over 30% in 52% of the cannabis-using group and by just 24% of the control group and that there were no serious adverse effects. The first joint smoke-cured by the cannabis-using patients reduced chronic pain by a median of seventy two compared to fifteen within the placebo cluster.
In 2009, a double-blind, placebo-controlled, crossover trial into the effectiveness of cannabis in reducing peripheral neuropathy found that of 28 subjects, neuropathy was reduced by over 30% in 46% of the cannabis-using cluster and eighteen of the management cluster, and that mood and general functioning were improved by a similar degree throughout the course of the study.
Disclaimer: the principles contained here is not designed nor meant to be a substitute for professional medical advice, it is only achieved for educational confidences only. You should take full responsibility for the way you decide on to use this information.